IMS 2022 | DETERMINATION: analysis of PFS benefit in different patient populations

Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the results of the DETERMINATION study (NCT01208662) in patients with high-risk multiple myeloma, and contrasts these findings with those of the DFCI 10-106 study (NCT01208662). Dr Richardson explains that the significant progression-free survival (PFS) benefit observed with early transplant in DETERMINATION is primarily due to continuous maintenance therapy with lenalidomide. In addition, the trial showed that high-risk patients particularly benefited from early transplant, with a trend suggesting an overall survival (OS) gain in those patients. Dr Richardson further highlights the importance of achieving MRD negativity, and discusses the results of the trial in the context of quadruplet therapies. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.